--Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating
10:05AM ET 5/23/2022 MT NewswiresPrice: 3.80, Change: +0.01, Percent Change: +0.26 ...
Quotes Snapshot > NXTC
NextCure Inc NXTC:NASDAQ
Last Price$4.50NASDAQ Closing Price as of 4:00PM ET 7/01/22
Today's Change-0.20(4.26%)
Bid (Size)$4.29 (1)
Ask (Size)$4.77 (1)
Day Low / High$4.48 - 4.75
Volume149.5 K
Read more news Recent News
--Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target
9:43AM ET 3/01/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating
12:37PM ET 11/05/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
NextCure (NXTC) Investor Presentation - Slideshow
3:26PM ET 6/15/2022 Seeking AlphaNextCure (NXTC) Presents At Global Healthcare Virtual Conference - Slideshow
5:49PM ET 2/25/2022 Seeking AlphaNextCure: Large Upside With Downside Protected By Cash Pile
8:07AM ET 9/29/2021 Seeking AlphaNextCure (NXTC) Presents At H. C. Wainwright 23rd Annual Global Investment Conference - Slideshow
3:46PM ET 9/16/2021 Seeking AlphaCompany Profile
Business DescriptionNextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. View company web site for more details
| Address | 9000 Virginia Manor Road Beltsville, Maryland 20705 |
| Phone | +1.240.399.4900 |
| Number of Employees | 44 |
| Recent SEC Filing | 06/24/2022 4 |
| President, Chief Executive Officer & Director | Michael S. Richman |
| Chief Operating Officer | Timothy Mayer |
| Chief Financial Officer | Steven P. Cobourn |
| Chief Scientific Officer | Solomon Langermann |
Company Highlights
| Price Open | $4.67 |
| Previous Close | $4.70 |
| 52 Week Range | $3.25 - 9.18 |
| Market Capitalization | $124.9 M |
| Shares Outstanding | 27.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.66 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -30.63% |
Analyst Ratings as of 05/31/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |